Indoco Remedies Limited
Franklin Templeton Mutual Fund, which previously held a 2.19 percent stake in Indoco Remedies Limited, no longer appears on the company's disclosed shareholder list, indicating either a complete exit or a reduction of its holding to below the 1 percent disclosure threshold.
A Mumbai-based pharmaceutical company engaged in manufacturing and marketing finished dosage formulations and active pharmaceutical ingredients for domestic and international markets. Indoco Remedies operates across formulations, contract manufacturing, and research divisions, maintaining vertically integrated operations spanning drug development, manufacturing, and distribution. The company serves healthcare providers and patients through its diverse pharmaceutical portfolio and specialized manufacturing capabilities.
Indian arm of Franklin Templeton Investments, a global AMC with over USD 1.5 trillion in assets worldwide. Manages over Rs 1.2 lakh crore in India. Navigated a significant setback when six debt schemes were wound up in April 2020 due to illiquid credit exposure, with full investor capital recovered by 2022. Equity franchise led by CIO Anand Radhakrishnan has maintained consistent performance through the volatility.